Medtronic divulges Type 2 diabetes outcomes data for MiniMed

Medtronic ($MDT) has released the latest study results from its MiniMed insulin pump/continuous glucose monitor. The 12-month data show that after crossing over to MiniMed from 6 months of multiple daily insulin (MDI) injections, A1C reduction improved from 0.4% to 0.8% while using 19% less insulin. The company said this is the largest randomized, controlled trial to compare efficacy and safety of insulin pumps versus multiple daily insulin injections in poorly controlled Type 2 diabetics. "We found that participants who switched from MDI to insulin pumps were able to achieve these same results by the 12-month mark," said Dr. Ronnie Aronson, the lead author of the continuation study phase and executive director at LMC Diabetes & Endocrinology in Canada in a statement. "Given that many patients with type 2 diabetes have difficulty achieving glycemic control, these additional data demonstrate that insulin pumps provide a significant advantage over MDI with a safe and consistent effect." More